Posted 3/25/2024
Scientists and clinicians whose discoveries have shaped the understanding of HIV disease will provide updates on the...
Posted 2/22/2024
There are many paths for women to travel to find success in science. That was a crucial theme conveyed by the four...
Posted 2/7/2024
Frederick National Laboratory researchers identified a vitamin A derivative (retinoid) that when combined with a...
All News
Antibody Therapy Could Be an Effective Method for HIV-1 Prevention, Treatment
Posted 5/21/2017Four recent studies have given the scientific community a better understanding of how human immunodeficiency virus (HIV) establishes and maintains itself in an infected individual and how antibody therapy may help prevent or fight the disease.
Current treatment for HIV infection depends on antiretroviral drug therapy (ART) to contain the infection in a host’s body. The…
Antibody Therapy Could Be an Effective Method for HIV-1 Prevention, Treatment
Posted 5/21/2017Four recent studies have given the scientific community a better understanding of how human immunodeficiency virus (HIV) establishes and maintains itself in an infected individual and how antibody therapy may help prevent or fight the disease.
Current treatment for HIV infection depends on antiretroviral drug therapy (ART) to contain the infection in a host’s body. The…
Inaugural Technology Showcase Aims to Increase Industry Partnerships and Commercialization of Cancer-Related Inventions
Posted 5/18/2017
Biotechnology stakeholders from across the region will have the opportunity to learn about cutting-edge technologies addressing urgent and intractable problems in cancer research at the 2017 Technology Showcase, to be held at the Frederick National Laboratory’s (FNL) Advanced Technology Research Facility (ATRF).
The inaugural half-day event, scheduled for June 7, will…
Frederick National Laboratory Rallies to Meet Demand for Zika Vaccine
Vaccine Clinical Materials ProgramPosted 5/9/2017The Frederick National Laboratory for Cancer Research is producing another round of Zika vaccine for ongoing studies to determine the best delivery method and dosage. This will lay the groundwork for additional tests to see if the vaccine prevents infection among volunteers in the United States and Central and South America.
David Lindsay, Ph.D., director of the national…
Extreme-Scale Computing Project Aims to Advance Precision Oncology
Posted 5/8/2017Two government agencies and five national laboratories are collaborating to develop extremely high-performance computing capabilities that will analyze mountains of research and clinical data to improve scientific understanding of cancer, predict drug response, and improve treatments for patients.
The cross-agency collaboration includes the National Cancer Institute and the…
Tech Transfer Award Hails FNL's Role in Ebola Response
Posted 5/2/2017For speeding the delivery of an effective candidate vaccine during the largest Ebola outbreak in history, the Frederick National Lab (as Leidos Biomed) was cited along with National Institute of Allergy and Infectious Diseases and GlaxoSmithKline in winning an Excellence in Technology Transfer Award from the Federal Laboratory Consortium for Technology Transfer.
The…
FNL Scientists Introduce Concept That Could Help the Immune System Respond to Vaccines
Posted 5/2/2017
Scientists have discovered an efficient and straightforward model to manipulate RNA nanoparticles, a new concept that could help trigger desirable activation of the immune system with vaccines and therapies.
A multi-institutional team of researchers used an approach to fine tune DNA and RNA nanoparticles to activate multiple biological functions and pathways. The group…
Large Cancer Drug Trial Helps Move Precision Medicine Toward the Mainstream
Posted 5/1/2017A landmark cancer drug trial is helping set the stage for moving precision medicine into the mainstream of clinical practice, according to a new study.
The study, reported in the Journal of Molecular Diagnostics, validates a procedure used in the drug trial that identifies the unique genetic mutations in a patient’s tumor, which is then used as the basis for selecting…
International Collaboration Will Explore New Drugs for RAS-Driven Cancers
Posted 4/25/2017FREDERICK, Md. -- An international collaboration has formed to begin an ambitious program of drug development and testing aimed at treating pancreatic cancers, lung cancers, and other malignancies driven by one of the most common and drug-resistant cancer genes.
Armed with new scientific understanding and the latest technologies, scientists at the Frederick National Lab and…
Frederick National Lab Supports Clinical Trials for Vaccine Against Mosquito-borne Chikungunya
Vaccine Clinical Materials ProgramPosted 4/11/2017An experimental vaccine for mosquito-borne chikungunya is being tested at sites in the Caribbean as part of a phase II clinical trial being managed by the Frederick National Lab.
No vaccine or treatment currently exists for the viral disease, which causes flu-like symptoms and severe joint pain that can be debilitating and long-lasting. The disease is common to tropical…
Media Inquiries
For all media related questions please contact:
Mary Ellen Hackett
Manager, Communications Office